A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
PHASE4CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
November 30, 2000
Primary Completion Date
September 30, 2005
Study Completion Date
September 30, 2005
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG
Fludarabine Phosphate (Fludara)
6 cycles (1 cycle: 5 treatment days every 28 days)
All Listed Sponsors
lead
Genzyme, a Sanofi Company
INDUSTRY
NCT00220311 - A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia | Biotech Hunter | Biotech Hunter